TG Therapeutics Inc Equity-NMS: TGTX

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$28.88
Open :	$28.37
Today's high :	$28.46
Today's low :	$27.4
52W low :	$12.84
52W high :	$36.84
1Y :	86.48%
5Y :	109.25%
EPS(TTM): :	-0.1
Shares O/S :	155.66 M
Market cap :	4.32 B

What is the share price of TG Therapeutics Inc today?

TG Therapeutics Inc (TGTX) share price as of January 10, 2025, is $28.88. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of TG Therapeutics Inc?

Yes, Indian Investors can invest in the TG Therapeutics Inc (TGTX) Share by opening an international trading account with Angel One.

How can I purchase TG Therapeutics Inc shares in India?

Purchasing TG Therapeutics Inc (TGTX) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying TG Therapeutics Inc (TGTX) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of TG Therapeutics Inc?

Yes, you can purchase fractional shares of TG Therapeutics Inc (TGTX) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of TG Therapeutics Inc?

The market capitalization of TG Therapeutics Inc on January 10, 2025, is $4.32 B.

In which sector TG Therapeutics Inc belongs?

TG Therapeutics Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in TG Therapeutics Inc stocks?

In order to invest in TG Therapeutics Inc (TGTX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.